Abstract
Valproic acid (VPA) is one of the most commonly used antiepileptic drugs and has broad indications for various types of epilepsy. Despite its broad spectrum, one of the most widely reported side effects of VPA is weight gain. The aim of this study was to determine the effect of demographic characteristics on genetic factors of CYP2C19 polymorphism in gender and weight changes. The research method used is analytic observational with a cross sectional study design involving two different groups and compared at the same time. Statistical analysis in this study using multiple linear regression. In observational results, it was known that the type of valproic acid (regular valproic acid and extended release) and free testosterone levels had a statistically significant effect on CYP2C19 polymorphisms (p < 0.05) in the body group. Meanwhile, in the gender group, it was found that female gender with a family history of obesity had a significant influence on the incidence of CYP2C19 polymorphisms, while characteristics such as age, dose, duration of therapy, type of epilepsy, free-testosterone levels, and total estradiol levels did not have a significant effect on CYP2C19 polymorphisms. Cytochrome (CYP) P450 enzymes play an important role in VPA metabolism).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
